Your session is about to expire
← Back to Search
Pembrolizumab for Non-Small Cell Lung Cancer
Study Summary
This trial will test if a specific gene mutation makes people more sensitive to a certain cancer drug, either by itself or in combination with another type of chemotherapy.
- Non-Small Cell Lung Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is this research endeavor currently accepting new participants?
"According to clinicaltrials.gov, the posting for this medical trial has not been updated since December 10th 2019 and is thus not currently recruiting patients. However there are 5688 active trials that may be accepting new participants."
What ailments is Pembrolizumab commonly administered for?
"Pembrolizumab is the primary medication used to address malignant neoplasms. This immunotherapy can also be successful in treating cases of unresectable melanoma, microsatellite instability high, and locally advanced nonsquamous non-small cell lung cancer."
How many participants are being monitored as part of this clinical experiment?
"The clinical trial is not currently recruiting patients, as it was last edited on December 10th 2019. For those who are still seeking medical trials to join, there are 3657 studies enrolling individuals with carcinoma or non-small cell lung cancer and 2031 investigations using pembrolizumab looking for participants."
What potential risks do patients face when taking Pembrolizumab?
"Our evaluation of Pembrolizumab's safety scored it a 2, as the Phase 2 trial has provided evidence that this medication is generally safe but there are no studies to prove its efficacy."
What other trials have been conducted pertaining to Pembrolizumab?
"Initially studied in 1997 at the City of Hope Comprehensive Cancer Center, pembrolizumab has since been part of an expansive body of research with 1971 completed studies. Currently there are 2031 live trials for this drug, some taking place in Philadelphia, Pennsylvania."
Share this study with friends
Copy Link
Messenger